BIOLINERX
Careers | Contact Us
search

Drugs in Developement

BL-1230 Dry Eye Syndrome
BL-1230

Indication: Dry Eye Syndrome
Mode of action: Anti-inflammatory
Stage of development: Pre-clinical
Patent status: Patents granted or pending in the USA, Europe and many other countries, valid at least until 2030

BL-1230 Overview

BL-1230 is a potent and selective cannabinoid receptor type 2 (CB2R) agonist intended as a novel treatment for Dry Eye Syndrome (DES). DES is a disease resulting in dryness, tear film instability, irritation, redness, itchy feeling, eye fatigue and even blurred vision, with potential damage to the ocular surface. DES can result from various reasons, including tear gland dysfunction, allergies, Sjogren’s syndrome, or as a side effect of certain medications or surgery. It is a common eye disease, affecting up to 30% of the global population to some degree, and can affect up to 70% of elderly people. Currently, treatment options are very limited, and include constant rehydration with artificial tears and local immunosuppressants.

The involvement of CB2R in immune modulation is well established, and pre-clinical studies in three ocular inflammatory models have demonstrated that BL-1230 eye drops have significant anti-inflammatory activity, which attenuates the pathology and improves histological outcomes. 

Inflammation is recognized as both a cause and consequence of DES and is a primary target in assessment and clinical treatment. BL-1230 not only targets inflammation via an immunomodulatory pathway that differs from current treatment options, but also may induce analgesic effects. In addition to DES, BioLineRx intends to explore the potential use of this compound in systemic inflammatory conditions.

BL-1230 was developed by Professor Raphael Mechoulam from the Department of Medicinal Chemistry and Natural Products at the Faculty of Medicine of the Hebrew University.

BL-1230 is being developed under an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. This is the third project in-licensed under the framework of the Company’s strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.

For more information: info@BioLineRx.com

Links :